Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

390
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
390
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

410
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
410
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

422
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
422
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The end of clinical freedom.

International journal of epidemiology·2011
Same author

Effect of aggregating agents on the electrophoretic mobility of human platelets.

British medical journal·2010
Same author

Microdisplacement printing.

Nano letters·2005
Same author

Thermally enhanced neutralization in hyperthermal energy ion scattering.

Physical review letters·2003
Same author

Size isn't everything.

Statistics in medicine·2002
Same author

Pathological features of witnessed out-of-hospital cardiac arrest presenting with ventricular fibrillation.

Resuscitation·2001

Related Experiment Video

Updated: May 5, 2026

Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior
10:05

Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior

Published on: September 16, 2015

15.8K

Mega-trials and equivalence trials: experience from the INJECT study.

J R Hampton1

  • 1Department of Cardiovascular Medicine, University Hospital, Nottingham NG7 2UH, U.K.

European Heart Journal
|September 1, 1996
PubMed
Summary

The INJECT trial demonstrated that reteplase (recombinant plasminogen activator) is equivalent to streptokinase in treating acute myocardial infarction. This finding supports reteplase as a viable alternative therapy for heart attack patients.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.1K
The Quantification of Injectability by Mechanical Testing
04:46

The Quantification of Injectability by Mechanical Testing

Published on: May 13, 2020

9.3K

Related Experiment Videos

Last Updated: May 5, 2026

Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior
10:05

Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior

Published on: September 16, 2015

15.8K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.1K
The Quantification of Injectability by Mechanical Testing
04:46

The Quantification of Injectability by Mechanical Testing

Published on: May 13, 2020

9.3K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute myocardial infarction (AMI) treatments have improved, reducing mortality rates.
  • New therapies offer marginal survival benefits, necessitating large trials for superiority.
  • Equivalence trials require smaller patient cohorts, making them efficient for comparing existing drug classes.

Purpose of the Study:

  • To determine if the novel agent reteplase (recombinant plasminogen activator) demonstrates mortality equivalence to streptokinase in AMI patients.
  • To assess the safety and efficacy of reteplase compared to streptokinase in a large patient population.

Main Methods:

  • The INJECT trial randomized 6010 patients with AMI to receive either reteplase (n=3004) or streptokinase (n=3006).
  • Patient outcomes including mortality, bleeding events, recurrent myocardial infarction, and stroke were monitored.
  • Statistical analysis focused on 35-day mortality rates and confidence intervals to establish equivalence.

Main Results:

  • Both groups showed similar rates of bleeding events, myocardial infarction recurrence, and disabling stroke.
  • Reteplase recipients experienced fewer in-hospital cardiac events and allergic reactions.
  • At 35 days, reteplase showed a 0.5% lower mortality rate than streptokinase, with a 90% confidence interval confirming equivalence.

Conclusions:

  • Reteplase is therapeutically equivalent to streptokinase for acute myocardial infarction based on the INJECT trial's predefined limits.
  • The study supports reteplase as a safe and effective alternative to streptokinase, with a favorable safety profile regarding allergic reactions.